Clinical trial

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622

Study summary

ClinicalTrials.gov

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention talazoparib plus enzalutamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo plus enzalutamide Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-05-12

PhasePHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

talazoparib plus enzalutamideDRUG

Placebo plus enzalutamideDRUG

Sponsors & collaborators

Pfizerlead sponsor

Astellas Pharma Inccollaborator

Mapped research locations

HoustonTexas, United States8 SeoulSouth Korea7 MontrealQuebec, Canada4 BudapestHungary4 JohannesburgGauteng, South Africa4 MadridSpain3 MoscowRussia3 WuhanHubei, China3 PlovdivBulgaria3 HelsinkiFinland3 PuneMaharashtra, India3 KingsportTennessee, United States3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04821622 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.